AMGN · CIK 318154
What Amgen Inc. told the SEC could break it.
Amgen's supply runs through a web of single points that are hard to swap because they're written into its regulatory filings: single-source contract manufacturers make all of its KRYSTEXXA drug substance in Israel (now exposed to the Middle East conflict) and its TEPEZZA drug substance, and it relies on one source for the SureClick autoinjectors that deliver Repatha and ENBREL — materials that can't be re-sourced without agency approval. At the other end, distribution is extremely concentrated: three wholesalers — McKesson, Cencora and Cardinal Health — are each over 10% of revenue and together 77% of worldwide gross revenue. Layered on is drug-pricing pressure, with ENBREL's net price down 36% on 340B mix and Medicare Part D redesign.
5 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- April 2025 universal 10% tariff EO (pharma exempted) and proposed sector-specific pharma tariffsmedium
The April 2025 Tariff EO imposed a universal 10% tariff on imported goods (with a pharmaceuticals exception) plus higher tariffs on ~60 trade-deficit countries; prior proposals for sector-specific pharma tariffs and ongoing trade-policy changes create uncertainty, partly mitigated by Section 232 relief Amgen received in December 2025 for U.S. manufacturing investment.
“On April 2, 2025, the Administration issued an executive order (the April 2025 Tariff EO) imposing a universal 10% tariff on all imported goods, with certain exceptions including pharmaceuticals. The April 2025 Tariff EO imposed additional higher tariffs on approximately 60 countries with which the United States has trade deficits.”
- ENBREL pricing pressure — 340B mix, Medicare Part D redesign, commercial discounts (-36% net price)medium
ENBREL U.S. sales fell 33% in 2025 driven by a 36% lower net selling price from increased 340B Program mix, U.S. Medicare Part D redesign and higher commercial discounts — illustrating drug-pricing-policy pressure on a major product.
“The decrease in ENBREL sales for 2025 was primarily driven by lower net selling price of 36% resulting from the impact of increased 340B Program mix, U.S. Medicare Part D redesign and higher commercial discounts, partially offset by volume growth of 4%.”
SEC filing →As of 2026
Customer concentration
- three wholesalers (McKesson, Cencora, Cardinal Health) = 77% of worldwide gross revenue, each >10%high
Amgen's product sales to three large wholesalers — McKesson, Cencora and Cardinal Health — each individually exceeded 10% of total revenues in 2025, and on a combined basis accounted for 77% of worldwide gross revenue, an extreme distribution-channel concentration.
“On a combined basis, these wholesalers accounted for 77%, 77% and 79% of worldwide gross revenue”
SEC filing →As of 2026
Geographic concentration
- single-source CMO for KRYSTEXXA drug substance in Israel (Middle East conflict); TEPEZZA CMO single-sourcehigh
Amgen relies on single-source CMOs including the one producing all KRYSTEXXA drug substance in Israel — affected by the current Middle East conflict — and the CMO producing TEPEZZA drug substance, concentrating critical drug-substance supply.
“many of which are single-source suppliers, including the CMO that produces TEPEZZA drug substance and the CMO that produces all of our KRYSTEXXA drug substance in Israel, which is affected by the current conflict in the Middle East.”
Sole-source dependency
- single-source SureClick autoinjectors (Repatha, ENBREL) and drug-application-cited sole-source materialshigh
Certain raw materials, medical devices and components are proprietary sole-source products cited in Amgen's regulatory drug applications and cannot be re-sourced without agency approval — e.g. Amgen relies on a single source for the SureClick autoinjectors used in Repatha, ENBREL and other products.
“we rely on a single source for the SureClick autoinjectors used in the drug delivery of a number of our products, including Repatha and ENBREL.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“Our product sales to three large wholesalers, McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., each individually accounted for more than 10% of total revenues for each of the years 2025, 2024 and 2023.”
Cited →“Our product sales to three large wholesalers, McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., each individually accounted for more than 10% of total revenues for each of the years 2025, 2024 and 2023.”
Cited →“Our product sales to three large wholesalers, McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., each individually accounted for more than 10% of total revenues for each of the years 2025, 2024 and 2023. On a combined basis, these wholesalers accounted for 77%, 77% and 79% of worldwide gross revenue”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch